Biosyngen Announces First-in-Human Dosing of Universal Off-the-Shelf CAR-Vδ1 T-cell Therapy UTAA06 in Solid Tumor Patient

However, the therapeutic effects of traditional cancer treatments such as surgery, radiotherapy, and chemotherapy are suboptimal, highlighting an urgent need to develop more effective clinical treatment methods. Recent studies indicate that a new generation of drugs targeting B7-H3 (such as CAR-T or ADC drugs) could become a promising option for improving treatment outcomes in patients with malignant solid tumors.The B7-H3-CAR-Vδ1T cell product independently developed by Bo Sheng Ji Medicine Science and Technology (Suzhou) Co., LTD exhibits excellent tumor homing and cytotoxic capabilities, is not restricted by MHC, and has the potential to be developed into a universal off-the-shelf cellular product.

A nearly 10,000-square-meter commercial production base meeting GMP standards has been completed. It is currently the leading fully automated CAR-T cell production base in the Asia-Pacific region. Inside, there are world-class GMP production and purification workshops for plasmids and lentiviruses, P2 safety laboratories, quality control rooms, and R&D laboratories. The facility boasts a complete production chain system from plasmids, lentiviruses to CAR-T cell preparation, with an entire industrial chain layout covering original innovation, quality control, commercial production, and cold chain transportation. It is one of the few companies in China that has built the most comprehensive fully automated and fully enclosed CAR-T cell production line.